🔗 Visit the ClinicalTrials.gov page for NCT02277522
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Engineered T cells: the promise and challenges of cancer immunotherapy. | Nat Rev Cancer | 2016 | 1.51 |
| 2 | Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. | Clin Cancer Res | 2016 | 0.95 |
| 3 | CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). | Ther Adv Hematol | 2015 | 0.95 |
| 4 | Trial Watch: Adoptive cell transfer for oncological indications. | Oncoimmunology | 2015 | 0.84 |
| 5 | Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. | Ther Adv Hematol | 2015 | 0.82 |
| 6 | Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. | Clin Exp Immunol | 2015 | 0.79 |
| 7 | Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. | Pediatr Blood Cancer | 2015 | 0.75 |